Panoptes Pharma (PP-001 marketing rights in two European countries) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Panoptes Pharma (PP-001 marketing rights in two European countries) General Information
Description
A marketing rights for pre-clinical development molecule in Austria. The asset features marketing rights of PP-001, a small molecule which is currently in preclinical development as potential next generation treatment for several inflammatory eye diseases including non-infectious uveitis in two European countries.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Acquirer
Laboratoires Leurquin Mediolanum
Primary Office
- Reisnerstraße 34/1
- Vienna, 1030
- Austria
Panoptes Pharma (PP-001 marketing rights in two European countries) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Panoptes Pharma (PP-001 marketing rights in two European countries) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|